BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. Dig Dis Sci. 2019;. [PMID: 30982212 DOI: 10.1007/s10620-019-05617-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Lucendo AJ. Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. Expert Rev Clin Immunol 2020;16:63-77. [PMID: 31842634 DOI: 10.1080/1744666X.2019.1705784] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Beales ILP. Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab. Dig Dis Sci 2019;64:2688-9. [DOI: 10.1007/s10620-019-05704-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chehade M, Kamboj AP, Atkins D, Gehman LT. Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study. The Journal of Allergy and Clinical Immunology: In Practice 2021;9:2050-2059.e20. [DOI: 10.1016/j.jaip.2020.12.054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hon E, Gupta SK. Gastrointestinal Food Allergies and Intolerances. Gastroenterol Clin North Am 2021;50:41-57. [PMID: 33518168 DOI: 10.1016/j.gtc.2020.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yamamoto M, Nagashima S, Yamada Y, Murakoshi T, Shimoyama Y, Takahashi S, Seki H, Kobayashi T, Hara Y, Tadaki H, Ishimura N, Ishihara S, Kinoshita Y, Morita H, Ohya Y, Saito H, Matsumoto K, Nomura I. Comparison of Nonesophageal Eosinophilic Gastrointestinal Disorders with Eosinophilic Esophagitis: A Nationwide Survey. J Allergy Clin Immunol Pract 2021:S2213-2198(21)00714-5. [PMID: 34214704 DOI: 10.1016/j.jaip.2021.06.026] [Reference Citation Analysis]
6 Wauters L, Burns G, Ceulemans M, Walker MM, Vanuytsel T, Keely S, Talley NJ. Duodenal inflammation: an emerging target for functional dyspepsia? Expert Opin Ther Targets 2020;24:511-23. [PMID: 32249629 DOI: 10.1080/14728222.2020.1752181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Dellon ES, Gonsalves N, Rothenberg ME, Hirano I, Chehade M, Peterson KA, Falk GW, Murray JA, Gehman LT, Chang AT, Singh B, Rasmussen HS, Genta RM. Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00592-9. [PMID: 34089846 DOI: 10.1016/j.cgh.2021.05.053] [Reference Citation Analysis]
8 Kinoshita Y, Ishihara S. Eosinophilic gastroenteritis: epidemiology, diagnosis, and treatment. Current Opinion in Allergy & Clinical Immunology 2020;20:311-5. [DOI: 10.1097/aci.0000000000000635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Chen PH, Anderson L, Zhang K, Weiss GA. Eosinophilic Gastritis/Gastroenteritis. Curr Gastroenterol Rep 2021;23:13. [PMID: 34331146 DOI: 10.1007/s11894-021-00809-2] [Reference Citation Analysis]
10 Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol 2019; 25(31): 4414-4426 [PMID: 31496621 DOI: 10.3748/wjg.v25.i31.4414] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
11 Lucendo AJ, López-Sánchez P. Targeted Therapies for Eosinophilic Gastrointestinal Disorders. BioDrugs 2020;34:477-93. [PMID: 32472465 DOI: 10.1007/s40259-020-00427-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
12 Pesek RD, Gupta SK. Future therapies for eosinophilic gastrointestinal disorders. Ann Allergy Asthma Immunol 2020;124:219-26. [PMID: 31778820 DOI: 10.1016/j.anai.2019.11.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
13 Olbrich CL, Simerly L, de Zoeten EF, Furuta GT, Spencer LA. Climbing New Mountains: How Antibodies Blocking α4β7 Integrins Tamed Eosinophilic Inflammation of the Intestinal Tract. Dig Dis Sci 2019;64:2068-71. [PMID: 31273593 DOI: 10.1007/s10620-019-05706-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Akhtar HJ, Nguyen TM, Ma C, Jairath V. Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00204-4. [PMID: 33618025 DOI: 10.1016/j.cgh.2021.02.026] [Reference Citation Analysis]
15 Pesek RD, Rothenberg ME. Eosinophilic gastrointestinal disease below the belt. J Allergy Clin Immunol 2020;145:87-89.e1. [PMID: 31669097 DOI: 10.1016/j.jaci.2019.10.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Pesek RD, Reed CC, Collins MH, Muir AB, Fulkerson PC, Menard-Katcher C, Falk GW, Kuhl J, Magier AZ, Ahmed FN, Demarshall M, Gupta A, Gross J, Ashorobi T, Carpenter CL, Krischer JP, Gonsalves N, Hirano I, Spergel JM, Gupta SK, Furuta GT, Rothenberg ME, Dellon ES; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. Dig Dis Sci 2020;65:2024-35. [PMID: 31773359 DOI: 10.1007/s10620-019-05961-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]